Salpingo-oophorectomy and the Risk of Ovarian, Fallopian Tube, and Peritoneal Cancers in Women With a BRCA1 or BRCA2 Mutation
暂无分享,去创建一个
Olufunmilayo I. Olopade | Amy Finch | Jan Lubinski | Charis Eng | Mary B. Daly | Fergus J. Couch | Ping Sun | Dominique Stoppa-Lyonnet | Henry T. Lynch | Peter Ainsworth | Jane McLennan | William D. Foulkes | Jeffrey N. Weitzel | Pål Møller | Beth Y. Karlan | Steven A. Narod | Eitan Friedman | Nadine Tung | Parviz Ghadirian | Charmaine Kim-Sing | Teresa Wagner | Barbara Pasini | Ruth Gershoni-Baruch | Joan Murphy | Mario E. Beiner | Barry P. Rosen
[1] K. Offit,et al. Prevention and management of hereditary breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] Susan L Neuhausen,et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. , 2002, The New England journal of medicine.
[3] T. Colgan,et al. Peritoneal lavage cytology: an assessment of its value during prophylactic oophorectomy. , 2002, Gynecologic oncology.
[4] J. Shepherd. Revised FIGO staging for gynaecological cancer , 1989, British journal of obstetrics and gynaecology.
[5] J Chang-Claude,et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. , 1998, American journal of human genetics.
[6] Rochelle L. Garcia,et al. Occult cancer of the fallopian tube in BRCA-1 germline mutation carriers at prophylactic oophorectomy: a case for recommending hysterectomy at surgical prophylaxis. , 2001, Gynecologic oncology.
[7] T. Colgan,et al. Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers. , 2006, Gynecologic oncology.
[8] M. King,et al. Breast and Ovarian Cancer Risks Due to Inherited Mutations in BRCA1 and BRCA2 , 2003, Science.
[9] M. Beattie,et al. Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] B. Rosen,et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. , 2001, American journal of human genetics.
[11] M. J. van de Vijver,et al. Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up , 2004, British Journal of Cancer.
[12] J. Hopper,et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. , 2003, American journal of human genetics.
[13] M. Piver,et al. Primary peritoneal carcinoma after prophylactic oophorectomy in women with a family history of ovarian cancer. A report of the gilda radner familial ovarian cancer registry , 1993, Cancer.
[14] Jacques Ferlay,et al. Cancer incidence in five continents. , 1976, IARC scientific publications.
[15] P. Hartge,et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. , 1997, The New England journal of medicine.
[16] Chen Kt,et al. Peritoneal carcinomatosis after prophylactic oophorectomy in familial ovarian cancer syndrome. , 1985 .
[17] J. Tobacman,et al. INTRA-ABDOMINAL CARCINOMATOSIS AFTER PROPHYLACTIC OOPHORECTOMY IN OVARIAN-CANCER-PRONE FAMILIES , 1982, The Lancet.
[18] J. Lubiński,et al. Cancer risks in first degree relatives of BRCA1 mutation carriers: effects of mutation and proband disease status , 2005, Journal of Medical Genetics.
[19] O. Olopade,et al. The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers. , 2005, Gynecologic oncology.
[20] T. Rebbeck,et al. Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] P. Hartge,et al. Gynecologic surgeries and risk of ovarian cancer in women with BRCA1 and BRCA2 Ashkenazi founder mutations: an Israeli population-based case-control study. , 2003, Journal of the National Cancer Institute.
[22] R. L. Baldwin,et al. Cancer incidence in a population of Jewish women at risk of ovarian cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] K. T. Chen,et al. Peritoneal Carcinomatosis After Prophylactic Oophorectomy in Familial Ovarian Cancer Syndrome , 1985, Obstetrics and gynecology.
[24] Mark E. Robson,et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation , 2002 .